Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) EBIT (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed EBIT for 15 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT fell 3.13% year-over-year to -$1.2 million, compared with a TTM value of -$4.1 million through Sep 2025, up 66.08%, and an annual FY2024 reading of -$4.8 million, up 85.96% over the prior year.
  • EBIT was -$1.2 million for Q3 2025 at Alaunos Therapeutics, down from -$1.0 million in the prior quarter.
  • Across five years, EBIT topped out at -$755000.0 in Q4 2024 and bottomed at -$22.6 million in Q2 2021.
  • Average EBIT over 5 years is -$8.2 million, with a median of -$8.3 million recorded in 2022.
  • The sharpest move saw EBIT fell 21.68% in 2021, then skyrocketed 90.5% in 2024.
  • Year by year, EBIT stood at -$11.1 million in 2021, then rose by 22.89% to -$8.5 million in 2022, then increased by 6.71% to -$7.9 million in 2023, then surged by 90.5% to -$755000.0 in 2024, then tumbled by 57.09% to -$1.2 million in 2025.
  • Business Quant data shows EBIT for TCRT at -$1.2 million in Q3 2025, -$1.0 million in Q2 2025, and -$1.1 million in Q1 2025.